Beatriz M. Carreno, PhD
Research Professor of Pathology and Laboratory MedicinePerelman School of Medicine at the University of Pennsylvania
Contact InformationPerelman School of Medicine at the University of Pennsylvania
Department of Pathology and Laboratory Medicine
Perelman Center for Advanced Medicine
South Tower, 8th Floor
3400 Civic Center Blvd
Philadelphia, PA 19104
Email: bcarreno@upenn.edu
Specialty Division
Cancer and Immunobiology
Research & Itmat Expertise
My research interests have centered on questions related to the generation and modulation of anti-tumor human T cell immunity and how these responses can be harnessed to develop better immune therapeutics. My laboratory develops methods for (1) identification of tumor antigens, (2) improvement of dendritic cell (DC)-based vaccines and (3) expansion of tumor-specific T cells for clinical applications. Our lab has well-documented experience in the identification and expansion of tumor (shared and neoantigen)-specific CD8+ T cells derived from cancer patients and the development of cellular immunotherapies.
Education
BS Universidad Simon Bolivar, Caracas, Venezuela, 1981
PhD (Microbiology), Georgetown University School of Medicine, 1989
Specialty Certification
Postgraduate Training
Visiting Postdoctoral Fellow, Neuro-immunology, NINDS, NIH, 1989-91
Postdoctoral Research Associate, Genetics, Washington University School of Medicine, 1991-95
Awards and Honors
Gran Mariscal de Ayacucho Scholarship, 1978
ITT International Fellowship, 1984-85
9th International Congress of Immunology Research Award, 1995
Memberships and Professional Organizations
American Association of Immunologists (AAI), 1993-present
American Association of Cancer Research (AACR), 2010-present
American Association for the Advancement of Science (AAAS), 2015-present
Center for Cellular Immunotherapies, University of Pennsylvania, 2016-present
Institute for Immunology and Immune Health (I3H; fka Institute for Immunology), Penn Medicine, 2016-present
Parker Institute for Cancer Immunotherapy, University of Pennsylvania, 2016-present
Pharmacology Graduate Group, University of Pennsylvania, 2017-present
Cell and Molecular Biology Graduate Group (CAMB), Gene Therapy and Vaccines Program, University of Pennsylvania, 2019-present (Admissions Committee, 2021-present)
University of Pennsylvania Human Immunology Core, Advisory Committee, 2019-present
French National Cancer Institute, 2020-present
Congressionally Directed Medical Research Programs (CDMRP), Panel Member, 2020-present
NCI, Special Emphasis Panel, ZCA1 RTRB-U (M1), Panel Member, 2022-present
NCI, Special Emphasis Panel, ZCA1 SRB-A (J1), Panel Member, 2022-present
Web Links
Selected Publications
Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations
Linette GP, Bear AS, Carreno BM. Clin Cancer Res 2024 Jan 24. doi: 10.1158/1078-0432.CCR-23-1212. Epub ahead of print. PMID: 38266167.
A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy
Lee IK, Sharma N, Noguera-Ortega E, Liousia M, Baroja ML, Etersque JM, Pham J, Sarkar S, Carreno BM, Linette GP, Puré E, Albelda SM, Sellmyer MA. Mol Ther 31(12):3564-3578, Dec 2023. doi: 10.1016/j.ymthe.2023.10.020. Epub 2023 Nov 3. PMID: 37919903; PMCID: PMC10727978.
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA. Blood Cancer Discov 4(2):118-133, Mar 2023. doi: 10.1158/2643-3230.BCD-22-0074. PMID: 36413381; PMCID: PMC9975770.
Expression of inducible factors reprograms CAR-T cells for enhanced function and safety
Smole A, Benton A, Poussin MA, Eiva MA, Mezzanotte C, Camisa B, Greco B, Sharma P, Minutolo NG, Gray F, Bear AS, Baroja ML, Cummins C, Xu C, Sanvito F, Goldgewicht AL, Blanchard T, Rodriguez-Garcia A, Klichinsky M, Bonini C, June CH, Posey AD Jr, Linette GP, Carreno BM, Casucci M, Powell DJ Jr. Cancer Cell 40(12):1470-1487, Dec 2022.e7. doi: 10.1016/j.ccell.2022.11.006. PMID: 36513049; PMCID: PMC10367115.
Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities
Olson TS, Frost BF, Duke JL, Dribus M, Xie HM, Prudowsky ZD, Furutani E, Gudera J, Shah YB, Ferriola D, Dinou A, Pagkrati I, Kim S, Xu Y, He M, Zheng S, Nijim S, Lin P, Xu C, Nakano TA, Oved JH, Carreno BM, Bolon YT, Gadalla SM, Marsh SG, Paczesny S, Lee SJ, Monos DS, Shimamura A, Bertuch AA, Gragert L, Spellman SR, Babushok DV. JCI Insight 7(22):e163040, Nov 2022. doi: 10.1172/jci.insight.163040. PMID: 36219480; PMCID: PMC9746824.
On the Twentieth Anniversary of Dendritic Cell Vaccines - Riding the Next Wave
Linette GP, Carreno BM. Cancer Res 82(6):966-968, Mar 2022. doi: 10.1158/0008-5472.CAN-21-4440. PMID: 35288731; PMCID: PMC9744103.
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments
Bhatta M, Shenoy GN, Loyall JL, Gray BD, Bapardekar M, Conway A, Minderman H, Kelleher RJ Jr, Carreno BM, Linette G, Shultz LD, Odunsi K, Balu-Iyer SV, Pak KY, Bankert RB. J Immunother Cancer 9(10):e003148, Oct 2021. doi: 10.1136/jitc-2021-003148. PMID: 34599030; PMCID: PMC8488709.
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, Baroja ML, McCuaig S, Costeas C, Gabunia K, Scholler J, Posey AD Jr, O'Hara MH, Smole A, Powell DJ Jr, Garcia BA, Vonderheide RH, Linette GP, Carreno BM. Nat Commun 12(1):4365, Jul 2021. doi: 10.1038/s41467-021-24562-2. PMID: 34272369; PMCID: PMC8285372.
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
Li L, Zhang X, Wang X, Kim SW, Herndon JM, Becker-Hapak MK, Carreno BM, Myers NB, Sturmoski MA, McLellan MD, Miller CA, Johanns TM, Tan BR, Dunn GP, Fleming TP, Hansen TH, Goedegebuure SP, Gillanders WE. Genome Med 13(1):56, Apr 2021. doi: 10.1186/s13073-021-00872-4. PMID: 33879241; PMCID: PMC8059244.
Preclinical evaluation of cancer immune therapy using patient-derived tumor antigen-specific T cells in a novel xenograft platform
Shenoy GN, Greene CJ, Bhatta M, Baroja ML, Loyall JL, Balu-Iyer SV, Kelleher RJ Jr, Carreno BM, Linette GP, Shultz LD, Bankert RB. Clin Transl Immunology 10(2):e1246, Feb 2021. doi: 10.1002/cti2.1246. PMID: 33552509; PMCID: PMC7853904.
